SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for SNP rs10079250

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma

The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A>G polymorphism as predictive biomarker

NCT04072042 Sarcoma Drug: Apatinib monotherapy
MeSH:Sarcoma
HPO:Sarcoma Soft tissue sarcoma

Correlation of CSF1R polymorphism (rs10079250) with wound complication.

Correlation of CSF1R (rs10079250) genotype with the incidence of wound complications among all comers.

Primary Outcomes

Description: The proportion of patients that are progression-free according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Measure: progression free rate (PFR)

Time: 4 months from recruitment

Secondary Outcomes

Description: The proportion of patients with negative biomarker that are progression-free according to RECIST 1.1

Measure: progression free rate (PFR) in biomarker negative sub-cohort

Time: 4 months from recruitment

Description: The difference of PFS between biomarker positive and biomarker negative sub-cohorts with log-rank test

Measure: progression free survival(PFS) between biomarker positive and negative sub-cohorts

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: Correlation of KDR 604 AA,AG,GG genotype with the incidence of pulmonary lesion cavitation or pneumothorax among all comers

Measure: Correlation of KDR polymorphism with pulmonary lesion cavitation/pneumothorax

Time: 4 months from recruitment

Description: Correlation of KDR 604 AA,AG,GG genotype with the incidence of hair depigmentation among all comers

Measure: Correlation of KDR polymorphism with hair depigmentation

Time: 4 months from recruitment

Description: Correlation of KDR 604 AA,AG,GG genotype with progression free survival according to RECIST 1.1 among all comers

Measure: Correlation of KDR polymorphism with progression-free survival(PFS)

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: The occurrence of each adverse events(AEs), severe AEs(SAEs) and death according the CTCAE_5.0

Measure: Incidence of Treatment-Emergent Adverse Events

Time: through study completion, an average of 8 months

Description: Correlation of CSF1R (rs10079250) genotype with the incidence of wound complications among all comers

Measure: Correlation of CSF1R polymorphism (rs10079250) with wound complication

Time: through study completion, an average of 8 months

Description: Correlation of PDGFRα (rs35597368) genotype with the incidence of hand foot skin reaction among all comers

Measure: Correlation of PDGFRα polymorphism (rs35597368) with hand foot skin reaction

Time: through study completion, an average of 8 months

Description: to correlate the incidence of targeted therapy related AEs (pulmonary lesion cavitation, pneumothorax, hair depigmentation) with the PFS

Measure: Early identification of AEs as predictive biomarker

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Other Outcomes

Description: The PFS for each subgroups in terms of clinicopathological characteristics (age, gender, histological type, solitary or multiple metastases, unilateral or bilateral metastases, early or late metastases, calcifying or non-calcifying lesions, with or without lesion cavitation, with or without AEs [especially pneumothorax, hand-foot skin reactions, hair depigmentation], etc

Measure: Exploratory outcome: Subgroup analysis of progression-free survival(PFS)

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: To explore the molecular basis underlying the difference of biomarker positive and negative sub-cohorts using next generation sequencing

Measure: Exploratory outcome: the molecular analysis of tumor sample

Time: through study completion, an average of 8 months

Description: to compare the growth pattern/ distribution of pulmonary versus extrapulmonary lesion at baseline and at disease progression between the two sub-cohorts

Measure: Exploratory outcome: the pattern of disease progression between the sub-cohorts

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months

Description: to compare the diagnostic value of the 1.0 mm versus 5.0 mm CT scan for the radiological evaluation of small lung nodule as tumor recurrence

Measure: Exploratory outcome: 1.0-mm CT scan for pulmonary assessment

Time: Baseline until disease progression or death, whichever occurs first, assessed for an average of 8 months


HPO Nodes